Lamegom

Agomelatine, the active ingredient in Lamegom, is a melatonin receptor agonist / 5-HT2C antagonist presented as a tablet for oral use. It treats major depressive disorder in adult patients by resynchronising circadian rhythms and improving mood. GNH USA supplies Lamegom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Agomelatine is indicated for major depressive disorder, a condition affecting mood, sleep and daily functioning. - Major depressive disorder: reduces depressive symptoms and helps restore normal sleep‑wake cycles.

Common Side Effects: - Headache: mild to moderate pain often occurring early in treatment. - Nausea: transient stomach upset that usually resolves. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Insomnia: difficulty falling or staying asleep. - Fatigue: feeling unusually tired or low‑energy. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury requiring monitoring. - Severe skin reactions: rash, Stevens‑Johnson syndrome, or toxic epidermal necrolysis. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Severe allergic reactions: anaphylaxis or angioedema. - QT prolongation: potential cardiac rhythm disturbances. - Pancreatitis: inflammation of the pancreas, presenting with abdominal pain and vomiting.

Before initiating therapy, clinicians should assess liver function and monitor periodically throughout treatment. - Liver monitoring: obtain baseline hepatic enzymes and repeat every 2–4 weeks. - CYP1A2 inhibitors: avoid concomitant strong inhibitors such as fluvoxamine. - Hepatic impairment: use with caution or avoid in patients with existing liver disease. - Suicidal risk: regularly evaluate for worsening depression or suicidal thoughts. - Pregnancy and lactation: prescribe only if benefits outweigh potential risks. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Agomelatine may interact with several medicines that affect its metabolism or hepatic safety. Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): can markedly increase agomelatine levels. - Hepatotoxic drugs (e.g., isoniazid, methotrexate): add to liver injury risk. - Oral contraceptives: may reduce agomelatine efficacy. Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., rifampicin, smoking): may lower drug exposure. - Alcohol: can exacerbate liver toxicity. - Other antidepressants with serotonergic activity: monitor for additive side effects.